Agape ATP Corporation — Form 10-Q Summary
Period: The filing covers the quarter and nine months ended March 31, 2018, with comparisons to March 31, 2017. This does not match the request metadata’s “2017 Q3.” Financial statements are unaudited; amounts are in U.S. dollars.
Business context and results
The development-stage company operates through subsidiaries in Malaysia and Hong Kong, offering health and wellness products and health-solution advisory services. It describes the ATP Zeta health program as a planned focus; reported nine-month sales were from healthy food products.
- Revenue: $0 for the three months ended March 31, 2018; $487,626 for the nine months, versus $0 in the comparable 2017 periods. All nine-month revenue was from one customer, identified as a related party whose director is Agape’s CEO and a director.
- Gross profit: $45,654 for the nine months, on cost of revenue of $441,972; gross margin was approximately 9.4%. No gross profit was reported for the March quarter.
- Net loss: The statements report $24,676 for the quarter and $202,015 for the nine months. The MD&A instead gives nine-month net loss of $196,333 and describes the quarter’s $28,856 loss before the investee result. The filing’s reported loss figures are therefore not fully consistent.
- Operating costs and tax: Nine-month administrative expense was $32,492, other operating expense was $215,393, and income tax provision was $5,682. The filing attributes losses primarily to higher professional fees and the investee result.
Cash flow, liquidity, and capital
- Cash and cash equivalents were $4.11 million at March 31, 2018, up from $2.31 million at June 30, 2017. Working capital was approximately $4.16 million.
- Nine-month operating cash use was $260,933; financing provided $2,925,500 from common-stock issuance. The cash-flow statement reports $863,592 used for the investee investment. MD&A gives a different investing cash-use figure of $893,592.
- Total liabilities were $11,609, including $3,927 due to a director; the director advance is unsecured, interest-free, and has no fixed repayment term. The filing reports no bank credit facilities.
- The company held an approximately 20% equity-method investment in Unreserved Sdn Bhd, carried at $867,772, including $4,180 of share of investee results. A director is common to both companies.
- Common shares outstanding increased to 374,275,500 from 371,350,000 at June 30, 2017. The filing reports no options, warrants, or other potentially dilutive securities.
Changes, outlook, and risks
- Compared with the prior-year periods, the company began reporting product revenue and recorded a net loss; the comparable 2017 statements show no revenue or loss. Management attributes sales growth to increased market exposure and new products introduced in 2017.
- Management says current capital resources are expected to cover basic operating needs for approximately 12 months. It expects marketing efforts and/or new products will be needed to retain and attract customers. No quantified revenue or earnings guidance is provided.
- Key risks include dependence on one customer for all reported revenue, reliance on prior equity financing, and the related-party nature of that customer relationship. Management reported disclosure controls were ineffective due to material weaknesses involving segregation of duties/risk assessment and insufficient written accounting and reporting procedures.
- The filing reports no commitments or contingencies, material legal proceedings, or significant off-balance-sheet arrangements, and no subsequent event requiring disclosure.
Most important facts to verify
- Reconcile the nine-month net loss ($202,015 in the statements versus $196,333 in MD&A and cash flows) and the quarter loss descriptions.
- Reconcile investing cash use ($863,592 in the cash-flow statement versus $893,592 in MD&A).
- Review the related-party customer relationship, the collectability of the $52,414 receivable, and whether revenue concentration continues.
- Assess the terms, valuation, and related-party governance of the Unreserved Sdn Bhd investment.
- Confirm progress addressing the disclosed material weaknesses and the basis for management’s 12-month liquidity expectation.